Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seebri

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

- PMLiVE

New hires at Bayer, Eisai and Accord Healthcare

The latest movers in pharma

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

AstraZeneca AZ

AZ builds case for its COPD triple as it chases GSK’s Trelegy

Awaiting approvals in Europe and the US

- PMLiVE

GSK files anaemia drug daprodustat in Japan, its first market

Around 3.5 million people in Japan could access the drug

- PMLiVE

Novartis chooses internal replacement for US pharma president role

Victor Bulto to lead US pharma business

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links